| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC3300 |
| Trial ID | NCT05674175 |
| Disease | T Cell Lymphoblastic Lymphoma | B-Cell Acute Lymphoblastic Leukemia |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CAR-T22-65s|CD19 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Co-administration of CART22-65s and huCART19 for B-ALL |
| Year | 2023 |
| Country | United States |
| Company sponsor | Stephan Grupp MD PhD |
| Other ID(s) | 22-020640|22CT015 |
| Cohort 1 | |||||||||
|
|||||||||